Literature DB >> 22442276

Association of intact parathyroid hormone levels with subsequent hip BMD loss: the Osteoporotic Fractures in Men (MrOS) Study.

Jeffrey R Curtis1, Susan K Ewing, Douglas C Bauer, Jane A Cauley, Peggy M Cawthon, Elizabeth Barrett-Connor, Elizabeth M Haney, Areef Ishani, Serge Cremers, Eric Orwoll.   

Abstract

INTRODUCTION: There is little information on the association between intact PTH (iPTH) and longitudinal changes in bone mineral density (BMD) in older men. This association was evaluated in relation to conditions related to higher iPTH [e.g. decreased renal function, low serum 25-hydroxyvitamin D (25[OH]D)].
METHODS: Eligible men were part of a random sample of 1593 community-dwelling individuals aged 65 yr or older participating in the Osteoporotic Fractures in Men study with baseline iPTH data. Of these, 1227 had at least two BMD measurements at the total hip and femoral neck over a mean follow-up of 4.5 yr. Annualized BMD change across iPTH quartiles was estimated using mixed-effects regression models, adjusting for age, serum calcium, serum 25(OH)D, estimated glomerular filtration rate, and other factors. Splines were used to identify more optimal iPTH thresholds associated with less BMD loss.
RESULTS: Among the cohort of 1138 eligible men, men in the highest quartile of iPTH (≥38 pg/ml) lost 0.46% per year at the total hip compared with men in the lowest iPTH quartile who lost 0.22% per year (P = 0.0004). Results were similar at the femoral neck. The association between iPTH and BMD loss was not modified by baseline estimated glomerular filtration rate or 25(OH)D status. Spline results suggested that iPTH levels below 30 pg/ml were more physiologically optimal than higher iPTH values in reducing BMD loss, although an exact threshold for optimal iPTH was not identified.
CONCLUSION: Older men with higher iPTH levels had approximately a 2-fold greater rate of BMD loss compared with men with lower iPTH levels, irrespective of estimated glomerular filtration rate and 25(OH)D.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22442276      PMCID: PMC3387420          DOI: 10.1210/jc.2011-2431

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  22 in total

1.  Flexible regression models with cubic splines.

Authors:  S Durrleman; R Simon
Journal:  Stat Med       Date:  1989-05       Impact factor: 2.373

2.  Third- or second-generation parathyroid hormone assays: a remaining debate in the diagnosis of primary hyperparathyroidism.

Authors:  Philippe Boudou; Fidaa Ibrahim; Catherine Cormier; Almécinda Chabas; Emile Sarfati; Jean-Claude Souberbielle
Journal:  J Clin Endocrinol Metab       Date:  2005-09-27       Impact factor: 5.958

3.  Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values.

Authors:  Andrew S Levey; Josef Coresh; Tom Greene; Jane Marsh; Lesley A Stevens; John W Kusek; Frederick Van Lente
Journal:  Clin Chem       Date:  2007-03-01       Impact factor: 8.327

4.  Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study--a large observational study of the determinants of fracture in older men.

Authors:  Eric Orwoll; Janet Babich Blank; Elizabeth Barrett-Connor; Jane Cauley; Steven Cummings; Kristine Ensrud; Cora Lewis; Peggy M Cawthon; Robert Marcus; Lynn M Marshall; Joan McGowan; Kathy Phipps; Sherry Sherman; Marcia L Stefanick; Katie Stone
Journal:  Contemp Clin Trials       Date:  2005-10       Impact factor: 2.226

5.  Overview of recruitment for the osteoporotic fractures in men study (MrOS).

Authors:  Janet Babich Blank; Peggy Mannen Cawthon; Mary Lou Carrion-Petersen; Loretta Harper; J Phillip Johnson; Eileen Mitson; Romelia Ramírez Delay
Journal:  Contemp Clin Trials       Date:  2005-10       Impact factor: 2.226

6.  The physical activity scale for the elderly (PASE): evidence for validity.

Authors:  R A Washburn; E McAuley; J Katula; S L Mihalko; R A Boileau
Journal:  J Clin Epidemiol       Date:  1999-07       Impact factor: 6.437

7.  Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy.

Authors:  Michael F Holick; Ethel S Siris; Neil Binkley; Mary K Beard; Aliya Khan; Jennifer T Katzer; Richard A Petruschke; Erluo Chen; Anne E de Papp
Journal:  J Clin Endocrinol Metab       Date:  2005-03-29       Impact factor: 5.958

8.  Drug data coding and analysis in epidemiologic studies.

Authors:  M Pahor; E A Chrischilles; J M Guralnik; S L Brown; R B Wallace; P Carbonin
Journal:  Eur J Epidemiol       Date:  1994-08       Impact factor: 8.082

9.  Serum 25-hydroxyvitamin D, parathyroid hormone, and bone mineral density in men: the Rancho Bernardo study.

Authors:  N Saquib; D von Mühlen; C F Garland; E Barrett-Connor
Journal:  Osteoporos Int       Date:  2006-09-12       Impact factor: 4.507

10.  Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure.

Authors:  M Rix; H Andreassen; P Eskildsen; B Langdahl; K Olgaard
Journal:  Kidney Int       Date:  1999-09       Impact factor: 10.612

View more
  14 in total

1.  The association between vitamin D and parathyroid hormone and bone mineral density: the Dong-gu Study.

Authors:  Seong-Woo Choi; Sun-Seog Kweon; Jin-Su Choi; Jung-Ae Rhee; Young-Hoon Lee; Hae-Sung Nam; Seul-Ki Jeong; Kyeong-Soo Park; So-Yeon Ryu; Hye-Rim Song; Min-Ho Shin
Journal:  J Bone Miner Metab       Date:  2015-07-30       Impact factor: 2.626

Review 2.  Idiopathic osteoporosis in men.

Authors:  Luigi Gennari; John P Bilezikian
Journal:  Curr Osteoporos Rep       Date:  2013-12       Impact factor: 5.096

3.  Parathyroid hormone reflects adiposity and cardiometabolic indices but not bone density in normal men.

Authors:  Emma O Billington; Greg D Gamble; Ian R Reid
Journal:  Bonekey Rep       Date:  2016-12-07

4.  Associations of 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D With Bone Mineral Density, Bone Mineral Density Change, and Incident Nonvertebral Fracture.

Authors:  Christine M Swanson; Priya Srikanth; Christine G Lee; Steven R Cummings; Ivo Jans; Jane A Cauley; Roger Bouillon; Dirk Vanderschueren; Eric S Orwoll; Carrie M Nielson
Journal:  J Bone Miner Res       Date:  2015-05-22       Impact factor: 6.741

Review 5.  Management of osteoporosis in older men.

Authors:  Jean-Marc Kaufman
Journal:  Aging Clin Exp Res       Date:  2021-04-05       Impact factor: 3.636

6.  Establishment of a normal reference value of parathyroid hormone in a large healthy Chinese population and evaluation of its relation to bone turnover and bone mineral density.

Authors:  M Li; F Lv; Z Zhang; W Deng; Y Li; Z Deng; Y Jiang; O Wang; X Xing; L Xu; W Xia
Journal:  Osteoporos Int       Date:  2016-01-05       Impact factor: 4.507

7.  A cross-sectional association between bone mineral density and parathyroid hormone and other biomarkers in community-dwelling young adults: the CARDIA study.

Authors:  Akira Fujiyoshi; Lynda E Polgreen; Daniel L Hurley; Myron D Gross; Stephen Sidney; David R Jacobs
Journal:  J Clin Endocrinol Metab       Date:  2013-08-21       Impact factor: 5.958

8.  Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations.

Authors:  Natalie E Cusano; Naim M Maalouf; Patty Y Wang; Chiyuan Zhang; Serge C Cremers; Elizabeth M Haney; Douglas C Bauer; Eric S Orwoll; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2013-05-20       Impact factor: 5.958

9.  Body composition and circulating estradiol are the main bone density predictors in healthy young and middle-aged men.

Authors:  S C Bilha; D Branisteanu; C Buzduga; D Constantinescu; P Cianga; E Anisie; A Covic; M C Ungureanu
Journal:  J Endocrinol Invest       Date:  2018-01-16       Impact factor: 4.256

Review 10.  Sex steroid actions in male bone.

Authors:  Dirk Vanderschueren; Michaël R Laurent; Frank Claessens; Evelien Gielen; Marie K Lagerquist; Liesbeth Vandenput; Anna E Börjesson; Claes Ohlsson
Journal:  Endocr Rev       Date:  2014-09-09       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.